Ipsen S.A. publishes its 2023 Consolidated Financial Statements

- 15 February 2024 - 1 mins read

Ipsen S.A. – 2023 Consolidated Financial Statements

Attachment

Related stories
14 October 2024 1 mins read

Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
29 June 2022 1 mins read

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
01 June 2021 1 mins read

Ipsen announces the launch of an Employee Shareholding Plan
See more stories

Related Press Releases

30 July 2026

Ipsen delivers excellent H1 2026 results and upgrades its full-year...
29 July 2026

Ipsen nominates Catherine Bradley to its Board of Directors as...
24 July 2026

Ipsen provides update on Phase III BOLD trial in biliary...
22 July 2026

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
13 July 2026

IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients...
09 July 2026

Dysport® is the first botulinum toxin to achieve positive topline...
01 July 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...
29 June 2026

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
28 May 2026

New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and...
19 May 2026

Ipsen announces late-breaking data from first head-to-head study comparing Dysport®...